RT Book, Section
A1 Donadini, Marco Paolo
A1 Douketis, James D.
A2 McKean, Sylvia C.
A2 Ross, John J.
A2 Dressler, Daniel D.
A2 Brotman, Daniel J.
A2 Ginsberg, Jeffrey S.
SR Print(0)
ID 56195401
T1 Chapter 61. Perioperative Management of Patients Who Are Receiving Oral Anticoagulant Therapy
T2 Principles and Practice of Hospital Medicine
YR 2012
FD 2012
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-160389-8
LK accessmedicine.mhmedical.com/content.aspx?aid=56195401
RD 2024/04/25
AB The  perioperative  management  of  patients  who  require  interruption  of  a  vitamin  K  antagonist  (VKA)  because  of  surgery  or  another  non-invasive  procedure  is  a  common  and  sometimes  challenging  clinical  problem.  Bridging  anticoagulation  refers  to  the  use  of  a  short-acting  anticoagulant,which  is  usually  therapeutic-dose  subcutaneous  low-molecular-weight  heparin  (LMWH)  such  as  enoxaparin  1  mg/kg  twice-daily,  administered  during  the  time  when  a  VKA  is  interrupted  and  there  is  no  therapeutic  anticoagulation.  However,  there  is  no  standardized  definition  of  ’bridging  anticoagulation’  and  other  treatment  regimens,  including  low-dose  (enoxaparin  40  mg  once-daily)  or  intermediate-dose  (eg,  enoxaparin  40  mg  twice-daily)  LMWH  regimens,  have  been  used,  particularly  in  selected  patients  at  high  risk  for  bleeding  complications.